An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-9

  Lal, Neeraj ^a   Beggs, Andrew D ^a   Willcox, Benjamin E ^a   Middleton, Gary W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Colorectal cancer; Immune signature; Microsatellite instability; RAS; Stratification

Indexed keywords

B RAF KINASE; K RAS PROTEIN; RAS PROTEIN;

ARTICLE; BIOINFORMATICS; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL INFILTRATION; CLUSTER ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84942824207     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.976052     Document Type: Article

References (46)

1. Galon J. Type, Density, and Location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
2. Galon J, Pagés F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G et al. Cancer classification using the Immunoscore: a worldwide task force. J Trans Med 2012; 10:205; PMID:23034130; http://dx.doi.org/10.1186/1479-5876-10-205
3. Galon J, Pagés F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Trans Med 2012; 10:1; PMID:22214470; http://dx.doi.org/10.1186/1479-5876-10-1
4. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH et al. Biomolecular network reconstruction identifies T-Cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429-40; PMID:19909745; http://dx.doi.org/10.1053/j.gastro.2009.10.057
5. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
6. Kim H, Nam SW, Rhee H, Shan Li L, Ju Kang H, Hye Koh K, Kyu Kim N, Song J, Tak-Bun Liu E, Kim H. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 2004; 23:6218-25; PMID:15208663; http://dx.doi.org/10.1038/sj.onc.1207853
7. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. British J Surg 2004; 91:469-75; PMID:15048750; http://dx.doi.org/10.1002/bjs.4472
8. Buckowitz A, Knaebel HP, Benner A, Bläker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. British J Cancer 2005; 92:1746-53; PMID:15856045; http://dx.doi.org/10.1038/sj.bjc.6602534
9. Banerjea A, Bustin SA, Dorudi S. The immunogenicity of colorectal cancers with high-degree microsatellite instability. World J Surg Oncol 2005; 3:26; PMID:15890075; http://dx.doi.org/10.1186/1477-7819-3-26
10. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-30; PMID:17204026; http://dx.doi.org/10.1111/j.1365-2559.2006.02549.x
11. Fehlker M, Huska MR, J€ons T, Andrade-Navarro MA, Kemmner W. Concerted down-regulation of immunesystem related genes predicts metastasis in colorectal carcinoma. BMC Cancer 2014; 14:64; PMID:24495478; http://dx.doi.org/10.1186/1471-2407-14-64
12. Boissiere-Michot F, Lazennec G, Frugier H, Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le Pessot F et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. OncoImmunology 2014; 3:e29256; PMID:25101223; http://dx.doi.org/10.4161/onci.29256
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
14. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
15. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T, Moreau J-F, Hayday AC, Willcox BE, Déchanet-Merville J. Cytomegalovirus and tumor stress surveillance by binding of a human gd T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 13:872-9; PMID:22885985; http://dx.doi.org/10.1038/ni.2394
16. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45:136-44; PMID:23263490; http://dx.doi.org/10.1038/ng.2503
17. Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H. HNPCC versus sporadic microsatelliteunstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007; 7:33; PMID:17316446; http://dx.doi.org/10.1186/1471-2407-7-33
18. Dienstmann R, Guinney J, Delorenzi M, De Reynies A, Roepman P, Sadanandam A, Vermeulen L, Schlicker A, Missiaglia E, Soneson C et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. ASCO Meeting Abstracts 2014; 32:3511.
19. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8C cytotoxic T lymphocyte response by cross-priming requires cognate CD4C T cell help. J Exp Med 1997; 186:65-70; PMID:9206998; http://dx.doi.org/10.1084/jem.186.1.65
20. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80; PMID:9624004; http://dx.doi.org/10.1038/30996
21. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4C T cells are required for secondary expansion and memory in CD8C T lymphocytes. Nature 2003; 421:852-6; PMID:12594515; http://dx.doi.org/10.1038/nature01441
22. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8C memory T cells. Nature 2006; 441:890-3; PMID:16778891; http://dx.doi.org/10.1038/nature04790
23. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(C) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651-67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921
24. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA et al. Tumor-reactive CD4(C) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918
25. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A et al. How Do CD4(C) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol 2014; 5:174; PMID:24782871; http://dx.doi.org/10.3389/fimmu.2014.00174
26. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4C T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/NEJMoa0800251
27. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al. Cancer immunotherapy based on mutation-specific CD4C T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
28. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
29. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580:755-62; PMID:16413538; http://dx.doi.org/10.1016/j.febslet.2005.12.093
30. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2011; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
31. Løvig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA, Rognum TO. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. British J Cancer 2002; 87:756-62; PMID:12232760; http://dx.doi.org/10.1038/sj.bjc.6600507
32. Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A et al. Frameshift-mutationderived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001; 98:13255-60; PMID:11687624; http://dx.doi.org/10.1073/pnas.231326898
33. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222:350-66; PMID:20927778; http://dx.doi.org/10.1002/path.2774
34. Maudsley DJ, Morris AG. Kirsten murine sarcoma virus abolishes interferon gamma-induced class II but not class I major histocompatibility antigen expression in a murine fibroblast line. J Exp Med 1988; 167:706-11; PMID:2831293; http://dx.doi.org/10.1084/jem.167.2.706
35. Maudsley DJ, Bateman WJ, Morris AG. Reduced stimulation of helper T cells by Ki-ras transformed cells. Immunology 1991; 72:277-81; PMID:1826672
36. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, St€orkel S, Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 2004; 109:265-73; http://dx.doi.org/10.1002/ijc.11681
37. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008; 20:228-33; PMID:18479894; http://dx.doi.org/10.1016/j.coi.2008.03.010
38. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:372-83; PMID:18799145; http://dx.doi.org/10.1016/j.immuni.2008.08.004
39. Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS. Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer Res 2012; 72:3260-9; PMID:22552288; http://dx.doi.org/10.1158/0008-5472.CAN-11-4141
40. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325:1593-6; PMID:1669840; http://dx.doi.org/10.1056/NEJM199112053252301
41. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. New Eng J Med 2012; 367:1596-606; PMID:23094721; http://dx.doi.org/10.1056/NEJMoa1207756
42. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP, Midgley R. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013; 31:4297-305; PMID:24062397; http://dx.doi.org/10.1200/JCO.2013.50.0322
43. Cbioportal for Cancer Genomics. Memorial Sloan Kettering Cancer Center.
44. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1.
45. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
46. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330-7; PMID:22810696; http://dx.doi.org/10.1038/nature11252